Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?.
Expert Opin Investig Drugs. 17(4), 445-9.
(2008). CORONA, statins, and heart failure: who lost the crown?.
Angiology. 59(1), 5-8.
(2008). Do we need to consider inflammatory markers when we treat atherosclerotic disease?.
Atherosclerosis. 200(1), 1-12.
(2008). Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients..
Am J Cardiol. 101(4), 483-5.
(2008). Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia..
Am J Cardiol. 101(11), 1679-80.
(2008). Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study..
Curr Med Res Opin. 24(6), 1593-9.
(2008). Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?.
Expert Opin Ther Targets. 12(7), 809-20.
(2008). Has the time come for a new definition of microalbuminuria?.
Curr Vasc Pharmacol. 6(2), 81-3.
(2008). High density lipoprotein cholesterol and statin trials..
Curr Med Chem. 15(22), 2265-70.
(2008). Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas..
Endocr Relat Cancer. 15(3), 693-700.
(2008). Omega-3 fatty acids: how can they be used in secondary prevention?.
Curr Atheroscler Rep. 10(6), 510-7.
(2008). Preventing macrovascular complications of diabetes: where do we stand with glycemic control?.
Expert Opin Investig Drugs. 17(12), 1777-9.
(2008). Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?.
Expert Opin Pharmacother. 9(9), 1437-40.
(2008). Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism..
Expert Opin Pharmacother. 9(4), 509-15.
(2008). Statins for the prevention of first or recurrent stroke..
Curr Vasc Pharmacol. 6(2), 124-33.
(2008). Unusual manifestation of diarrhea-associated haemolytic uraemic syndrome in an adult..
Ren Fail. 30(3), 331-4.
(2008). Adrenal incidentaloma: a diagnostic challenge..
Hormones (Athens). 8(3), 163-84.
(2009). Anti-inflammatory effects of fibrates: an overview..
Curr Med Chem. 16(6), 676-84.
(2009). Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?.
Angiology. 60(4), 397-402.
(2009). Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?.
Angiology. 60(1), 74-81.
(2009). Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis..
J Clin Endocrinol Metab. 94(8), 2692-701.
(2009). Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus..
Nat Clin Pract Endocrinol Metab. 5(1), 16-7.
(2009). A comparison of the aldosterone-blocking agents eplerenone and spironolactone..
Clin Cardiol. 32(4), 230.
(2009). Dyslipidemia as a risk factor for ischemic stroke..
Curr Top Med Chem. 9(14), 1291-7.
(2009). Implementation of guidelines for the management of arterial hypertension. The impulsion study..
Open Cardiovasc Med J. 3, 26-34.
(2009).